Principia Biopharma, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Principia Biopharma, Inc.
Looking to treat patients with CSU uncontrolled by Xolair, Celldex’s KIT binder barzolvolimab shows strong disease activity reduction at 12 weeks in Phase II. Sanofi’s BTK inhibitor rilzabrutinib also showed efficacy in CSU.
SR One will keep investing in a mix of new companies, early-stage firms and later opportunities with its second fund, raised even as biotech continues to endure challenging financial times.
The firm’s BTK inhibitor tolebrutinib has been put on clinical hold by the US FDA following liver injuries, but advanced trials should continue as normal since most patients have passed the 60-day mark.
BTK inhibitors are in late-stage development for multiple sclerosis, with Merck KgAA and Sanofi in the lead and Roche and Novartis close behind.
Drug Discovery Tools
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.